BI
MGX icon

Bramshill Investments’s Metagenomi Therapeutics MGX Stock Holding History

Bramshill Investments’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,500
Closed -$63.2K – 193
2024
Q2 		$63.2K Sell
15,500
-10,000
-39% -$68.7K 0.01% 143
2024
Q1 		$269K Buy
+25,500
New +$293K 0.03% 99

Other funds holding MGX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bramshill Investments's MGX Position: Q3 2024 in Review

Bramshill Investments sold out of Metagenomi Therapeutics (MGX) in Q3 2024, closing a stake of 15,500 shares — an estimated $63.2K sold.

Bramshill Investments first reported a position in MGX in Q1 2024 and held it in 2 quarters. The position peaked at $269K in Q1 2024. 67 funds tracked by Wall St. Rank hold MGX as of Q3 2024.

  • Bramshill Investments reported no remaining Metagenomi Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bramshill Investments sold 15,500 Metagenomi Therapeutics shares in Q3 2024, an estimated $63.2K.
  • Bramshill Investments first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 2 quarters.
  • Bramshill Investments's Metagenomi Therapeutics position peaked at $269K in Q1 2024.
  • 67 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2024.

Based on Bramshill Investments's 13F filing for Q3 2024, filed 13 Nov 2024.